InsiderSignal.AI

InsiderSignal.ai

ACLX - Arcellx, Inc.

Insider Sale by Gilson Michelle (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Gilson Michelle, serving as CFO at Arcellx, Inc. (ACLX), sold 11,219 shares at $113.82 per share, for a total transaction value of $1,276,954.00. Following this transaction, Gilson Michelle now holds 33,938 shares of ACLX.

This sale represents a 25.00% decrease in Gilson Michelle's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, February 25, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 25, 2026, meaning the disclosure happened on the same day as the trade.

Arcellx, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gilson Michelle

CFO

Michelle Gilson is the Chief Financial Officer (CFO) of Arcellx, Inc. (ACLX), a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. She joined Arcellx in May 2022, recruited by CEO Rami Elghandour, bringing her extensive expertise in biotech equity research to support capital raising, financial reporting, and investor relations amid a challenging funding environment.[[1]](https://www.canaccordgenuity.com/women-entrepreneurs/meet-our-advisors/michelle-gilson/)[[2]](https://www.cfo.com/news/from-analyst-to-cfo-by-age-30-michelle-gilson/654940/)[[3]](https://news.biobuzz.io/2025/07/16/5-questions-with-michelle-gilson-cfo-of-arcellx/)[[4]](https://www.arcellx.com/company/)[[6]](https://www.prnewswire.com/news-releases/arcellx-appoints-michelle-gilson-as-chief-financial-officer-301551505.html) Prior to Arcellx, Gilson spent nearly a decade on Wall Street as a biotech equity research analyst, most recently as Managing Director and Senior Equity Research Analyst at Canaccord Genuity Group Inc. from April 2021 to May 2022, and previously at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. She earned a B.S. in Business Administration from the University of Southern California and became CFO at age 30, leveraging her sell-side experience to drive Arcellx's public stock offering that raised $128.8 million in June 2022.[[1]](https://www.canaccordgenuity.com/women-entrepreneurs/meet-our-advisors/michelle-gilson/)[[2]](https://www.cfo.com/news/from-analyst-to-cfo-by-age-30-michelle-gilson/654940/)[[3]](https://news.biobuzz.io/2025/07/16/5-questions-with-michelle-gilson-cfo-of-arcellx/)[[4]](https://www.arcellx.com/company/)[[7]](https://www.benzinga.com/sec/insider-trades/0001930862/michelle-gilson)

View full insider profile →

Trade Price

$113.82

Quantity

11,219

Total Value

$1,276,954.00

Shares Owned

33,938

Trade Date

Wednesday, February 25, 2026

2 days ago

SEC Filing Date

Wednesday, February 25, 2026

HEALTHCAREBIOTECHNOLOGY

About Arcellx, Inc.

Company Overview

No company information available
View news mentioning ACLX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4300157

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime